• Home
  • Sava Healthcare Ltd

Sava Healthcare Ltd

About Sava Healthcare Ltd

Established in 2003, Sava Healthcare is a pharmaceutical company headquartered in Pune, India.

Our Manufacturing Facility is situated within our expansive 15,000 sq. ft. facility, which proudly holds accreditation from Health Canada & PIC/s (Ukraine). We specialise in various dosage forms, including Tablets, Oral powders for Suspension, Nasal Sprays, Capsules, Ointments, Creams, and Gels. We are on track for EU-GMP approval for tablets and nasal sprays. 

We have a nasal spray product pipeline for out-licensing, developed for EU markets. 


Read more Show less
Certifications
  • GMP
    GMP
  • Other
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • IN
  • 2019
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Pharmaceutical company
Veterinary Company
Primary activities
Contract Manufacturer
Out-licensing specialist
Pharmaceutical Company (generic finished products)
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI & PMEC India 2024

India Expo Centre, Greater Noida, Delhi NCR
26 Nov 2024 - 28 Nov 2024
View Exhibitor Profile

CPHI Frankfurt 2025

Messe, Frankfurt
28 Oct 2025 - 30 Oct 2025
View Exhibitor Profile

Products from Sava Healthcare Ltd (2)

Sava Healthcare Ltd Resources (1)

  • News SAVA Healthcare to set up second manufacturing plant in Indore

    SAVA Healthcare conducted the ground-breaking ceremony of its second manufacturing plant, in the Smart Industrial Park (SIP) of Madhya Pradesh Industry Development Corporation (MPIDC) in March.

    SAVA Healthcare currently operates a Health Canada, PIC/s approved facility in Gujarat’s Surendranagar and an R&D centre in Pune.

    The proposed second plant will have a projected annual production capacity of 2,351.3 million SKUs which will include tablets, capsules, dry powder for oral suspension, ointments, nasal sprays, and dry powders for inhalation.

    Situated on 13.8 acres of prime land, the forthcoming facility will reportedly meet stringent regulatory standards such as EUGMP / USFDA of global pharma markets.
    15 Apr 2024